Moreover, any benefits of monoclonal antibodies against cognitive decline in patients with AD who are at high risk of ischemic stroke, should be carefully weighed against the contraindication for intravenous tissue plasminogen activator in the event of a stroke whilst on monoclonal antibodies against amyloid-β [33]. Here, PLAT is linked to ischemic stroke.